INBRX-106 Hexavalent Anti-OX40 Agonist Inhibrx Solid Tumors

INBRX-106 is a hexavalent anti-OX40 agonist developed by Inhibrx for solid tumor treatment, engineered with modular single domain antibody technology to achieve superior potency compared to bivalent antibodies. Preclinical data demonstrates enhanced co-stimulatory capacity and anti-tumor activity, with synergy when combined with checkpoint modulators like pembrolizumab. The company has initiated a Phase 1 clinical trial to evaluate INBRX-106 as a single agent and in combination therapy.